BRAF and Miyoshi myopathy: Approved BRAF inhibitors already exist (e.g., vemurafenib), which is relevant for 5–10% of MM patients with the aggressive BRAF V600E-mutant form of the disease and opens possibilities for personalized combination strategies [44].